Protalix Biotherapeutics Inc. (PLX)
NYSE · Healthcare
Protalix Biotherapeutics Inc. Shareholder Equity 2009–2025
Protalix Biotherapeutics Inc. annual shareholder equity history from 2010 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Protalix Biotherapeutics Inc. shareholder equity as of December 31, 2025: 48.2M, a 11.62% increase year-over-year.
- Protalix Biotherapeutics Inc. shareholder equity for 2025 were 48.2M, a 11.62% increase from 2024.
- Protalix Biotherapeutics Inc. shareholder equity for 2024 were 43.2M, a 28.72% increase from 2023.
- Protalix Biotherapeutics Inc. shareholder equity for 2023 were 33.6M, a 415.50% decrease from 2022.
- Protalix Biotherapeutics Inc. shareholder equity for 2022 were -10.6M.
Shareholder Equity
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| Protalix Biotherapeutics Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $48 |
| 2024 | $43 |
| 2023 | $34 |
| 2022 | $-11 |
| 2021 | $-6 |
| 2020 | $-27 |
| 2019 | $-70 |
| 2018 | $-53 |
| 2017 | $-29 |
| 2016 | $-10 |
| 2015 | $11 |
| 2014 | $-56 |
| 2013 | $-27 |
| 2012 | $-3 |
| 2011 | $-26 |
Protalix Biotherapeutics Inc. Shareholder Equity — FAQ
Protalix Biotherapeutics Inc. (PLX) shareholder equity over the last 17 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see PLX's shareholder equity history?
The chart and table above show Protalix Biotherapeutics Inc.'s shareholder equity by year and by quarter, including the growth rate.